Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell NewsScientists report the efficacy of anti-programmed death 1 antibody with the P-GEMOX (pegaspargase, gemcitabine, and oxaliplatin) regimen in advanced natural killer/T cell lymphoma.
[Signal Transduction and Targeted Therapy]
6445218 NIW37BLL items 1 apa 0 default asc 1 157586 https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-4bf72873c8a97c67591d415a4a2cfd0a%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22NIW37BLL%22%2C%22library%22%3A%7B%22id%22%3A6445218%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Cai%20et%20al.%22%2C%22parsedDate%22%3A%222020-12-30%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ECai%2C%20J.%2C%20Liu%2C%20P.%2C%20Huang%2C%20H.%2C%20Li%2C%20Y.%2C%20Ma%2C%20S.%2C%20Zhou%2C%20H.%2C%20Tian%2C%20X.%2C%20Zhang%2C%20Y.%2C%20Gao%2C%20Y.%2C%20Xia%2C%20Y.%2C%20Zhang%2C%20X.%2C%20Yang%2C%20H.%2C%20Li%2C%20L.%2C%20%26amp%3B%20Cai%2C%20Q.%20%282020%29.%20Combination%20of%20anti-PD-1%20antibody%20with%20P-GEMOX%20as%20a%20potentially%20effective%20immunochemotherapy%20for%20advanced%20natural%20killer%5C%2FT%20cell%20lymphoma.%20%3Ci%3ESignal%20Transduction%20and%20Targeted%20Therapy%3C%5C%2Fi%3E%2C%20%3Ci%3E5%3C%5C%2Fi%3E%281%29%2C%201%26%23x2013%3B9.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41392-020-00331-3%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41392-020-00331-3%3C%5C%2Fa%3E%20%3Ca%20title%3D%27Cite%20in%20RIS%20Format%27%20class%3D%27zp-CiteRIS%27%20href%3D%27https%3A%5C%2F%5C%2Fwww.stemcellsciencenews.com%5C%2Fwp-content%5C%2Fplugins%5C%2Fzotpress%5C%2Flib%5C%2Frequest%5C%2Frequest.cite.php%3Fapi_user_id%3D6445218%26amp%3Bitem_key%3DNIW37BLL%27%3ECite%3C%5C%2Fa%3E%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Combination%20of%20anti-PD-1%20antibody%20with%20P-GEMOX%20as%20a%20potentially%20effective%20immunochemotherapy%20for%20advanced%20natural%20killer%5C%2FT%20cell%20lymphoma%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jun%22%2C%22lastName%22%3A%22Cai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Panpan%22%2C%22lastName%22%3A%22Liu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Huiqiang%22%2C%22lastName%22%3A%22Huang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yajun%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shuyun%22%2C%22lastName%22%3A%22Ma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hui%22%2C%22lastName%22%3A%22Zhou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xiaopeng%22%2C%22lastName%22%3A%22Tian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yuchen%22%2C%22lastName%22%3A%22Zhang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yan%22%2C%22lastName%22%3A%22Gao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yi%22%2C%22lastName%22%3A%22Xia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xuanye%22%2C%22lastName%22%3A%22Zhang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hang%22%2C%22lastName%22%3A%22Yang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lirong%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Qingqing%22%2C%22lastName%22%3A%22Cai%22%7D%5D%2C%22abstractNote%22%3A%22Advanced%20natural%20killer%5C%2FT%20cell%20lymphoma%20%28NKTL%29%20has%20demonstrated%20poor%20prognosis%20with%20currently%20available%20therapies.%20Here%2C%20we%20report%20the%20efficacy%20of%20anti-programmed%20death%201%20%28PD-1%29%20antibody%20with%20the%20P-GEMOX%20%28pegaspargase%2C%20gemcitabine%2C%20and%20oxaliplatin%29%20regimen%20in%20advanced%20NKTL.%20Nine%20patients%20underwent%20six%2021-day%20cycles%20of%20anti-PD-1%20antibody%20%28day%201%29%2C%20pegaspargase%202000%5Cu2009U%5C%2Fm2%20%28day%201%29%2C%20gemcitabine%201%5Cu2009g%5C%2Fm2%20%28days%201%20and%208%29%20and%20oxaliplatin%20130%5Cu2009mg%5C%2Fm2%20%28day%201%29%2C%20followed%20by%20anti-PD-1%20antibody%20maintenance%20every%203%20weeks.%20Programmed%20death-ligand%201%20%28PD-L1%29%20expression%20and%20genetic%20alterations%20were%20determined%20in%20paraffin-embedded%20pretreatment%20tissue%20samples%20using%20immunohistochemistry%20and%20next-generation%20sequencing%20%28NGS%29%20analysis.%20Responses%20were%20assessed%20using%2018F-fluorodeoxyglucose%20positron%20emission%20tomography%20%2818FDG-PET%29%20and%20computed%20tomography%20or%20magnetic%20resonance%20imaging.%20Eight%20patients%20exhibited%20significant%20responses%2C%20comprising%20of%20seven%20complete%20remissions%20and%20one%20partial%20remission%20%28overall%20response%20rate%3A%2088.9%25%29.%20After%20a%20median%20follow-up%20of%2010.6%20months%2C%206%5C%2F9%20patients%20%2866.7%25%29%20remained%20in%20complete%20remission.%20The%20most%20common%20grade%203%5C%2F4%20adverse%20events%20were%20anemia%20%2833.3%25%29%2C%20neutropenia%20%2833.3%25%29%2C%20and%20thrombocytopenia%20%2833.3%25%29%3B%20all%20of%20which%20were%20manageable%20and%20resolved.%20Immunochemotherapy%20produced%20a%20high%20response%20rate%20in%20patients%20with%20positive%20PD-L1%20expression%20%285%5C%2F6%2C%2083.3%25%29.%20NGS%20analysis%20suggested%20that%20STAT3%5C%2FJAK3%5C%2FPD-L1%20alterations%20and%20ARID1A%20mutation%20were%20associated%20with%20immunochemotherapy%20efficacy.%20Mutation%20in%20DDX3X%20and%20alteration%20in%20epigenetic%20modifiers%20of%20KMT2D%2C%20TET2%2C%20and%20BCORL1%20might%20indicate%20a%20poor%20response%20to%20immunochemotherapy.%20In%20conclusion%2C%20the%20anti-PD-1%20antibody%20plus%20P-GEMOX%20regimen%20demonstrated%20promising%20efficacy%20in%20advanced%20NKTL.%20PD-L1%20expression%20combined%20with%20specific%20genetic%20alterations%20could%20be%20used%20as%20potential%20biomarkers%20to%20predict%20therapeutic%20responses%20to%20immunochemotherapy.%22%2C%22date%22%3A%222020-12-30%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41392-020-00331-3%22%2C%22ISSN%22%3A%222059-3635%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.nature.com%5C%2Farticles%5C%2Fs41392-020-00331-3%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-01-05T03%3A17%3A49Z%22%7D%7D%5D%7D
Cai, J., Liu, P., Huang, H., Li, Y., Ma, S., Zhou, H., Tian, X., Zhang, Y., Gao, Y., Xia, Y., Zhang, X., Yang, H., Li, L., & Cai, Q. (2020). Combination of anti-PD-1 antibody with P-GEMOX as a potentially effective immunochemotherapy for advanced natural killer/T cell lymphoma. Signal Transduction and Targeted Therapy, 5(1), 1–9. https://doi.org/10.1038/s41392-020-00331-3 Cite
